Library

Assessing the economic value of anti-cancer therapies / Niels Neymark / New York ; Berlin ; Tokyo : Springer (1998)

Assessing the economic value of anti-cancer therapies [printed text] / Niels Neymark . - New York ; Berlin ; Tokyo : Springer, 1998 . - XI, 285 p. ; 23 cm. - (Recent results in cancer research; 148) . ISBN : 978-3-540-64030-1 Languages : English (eng) Descriptors: Classification QZ 266 Neoplasms. Cysts -- Therapy Indexation Antineoplastic Agents ; Cost-Benefit Analysis ; Costs and Cost Analysis ; Economic Evaluation ; Health Care Costs ; Neoplasms Abstract: BOOK REVIEW Kevin B. Knopf, JNCI, 1999, 91(14), 1248-1249 The need for accurate economic analysis to guide health care delivery is irrefutable, since health care costs continue to rise in parallel with a growing demand in value for our spending. Cancer care accounts for 5%-10% of all health care dollars spent in the United States, and although breakthroughs in cancer research will provide much needed improvements in the treatment of cancer, they will also come at a cost. Dr. Neymark speaks in his preface of the "aura of sanctity" surrounding cancer so that "everything possible" is done for the patients. This aura derives partly from the seriousness of the disease and the fear surrounding a diagnosis of cancer. However, a need for high-quality economic research in cancer care is still necessary to guide rational resource allocation, and this text succeeds in succinctly and thoughtfully summarizing the state of the art of economic analysis of cancer therapies. By exploring the literature related to economic evaluation of cancer therapies over a 10-year period, Dr. Neymark has provided a great deal of food for thought for research in this area. The general nature of economic evaluation is defined in the introduction: "Economic evaluation is a widely applicable economic method concerned with the comparison of two or more alternatives with respect to both their positive and negative impacts or benefits and costs, respectively, as these impacts are generally termed. It is the presence of alternative methods of treatments that create an economic problem." It is the presence of choices that makes economic evaluation a valuable tool. In the past, the treatment of cancer, particularly metastatic disease, was limited in the number of options available, as the author notes. However, new treatments are continually being developed, which come with a cost versus benefit trade-off, and thus economic evaluations will assume a greater importance as our therapeutic choices increase. The very brief chapter on the epidemiology of cancer could have been made more substantial, and the addition of graphs to interpret trends would have been useful. The following chapter provides an excellent overview of the nature of cancer and its major treatment modalities, which will be of interest to the nonclinician. The chapters on economic evaluation and the economic burden of cancer are well written and serve as solid introductions for the novice to these areas and a good review for others. He describes the rationale and methods behind the cost-of-illness studies, which he treats with a healthy skepticism. A lengthy section on economic evaluation covers important concepts and describes, in turn, the four major types of studies: cost-minimization, cost-benefit, cost-effectiveness, and cost-utility, the latter two being the most appropriate type of study for most cancer therapeutics. Discussion about methodology involved in collecting data for cost and outcomes, perspective of the analysis, valuation, and presentation and interpretation of results of economic evaluations are also well written. The heart of the text is a thorough discussion of the major economic studies of cancer treatment published from 1985 to 1996. The author reviews the relevant literature pertaining to costs and treatment of most of the major malignancies, including relevant supportive care areas. Topics covered include the following: breast cancer (14 studies), lung cancers (eight studies), colorectal cancer (eight studies), prostate cancer (10 studies), genitourinary and gynecologic malignancies (11 studies), leukemias and lymphomas (10 studies), therapies for emesis and infections (nine studies), hematologic support and transplantation (18 studies), and palliative care (five studies). Every section is preceded by an overview of treatment options that are fairly accurate—although not without occasional omissions and errors; these sections will be invaluable for the nonclinician. Each study is described concisely, including rationale, type of analysis, perspective, techniques, data sources, and results, when stated by the original authors. Dr. Neymark justly criticizes studies with conceptual or methodologic flaws, erroneous assumptions, or clear oversights in the evaluation, and as a critical reviewer, he certainly holds no punches. This lengthy and in-depth review of a body of work makes his text a compelling read and enables the reader to gain a great deal of insight into how to, and often how not to, evaluate the economics of cancer therapeutics. Through reading his summation of the body of literature, one obtains an appreciation of not only what studies have been performed and which studies should be performed but also a sense of the "state of the art of the methodology" currently in use. Each chapter closes with a concise table of the articles reviewed and concluding comments that highlight the strengths and weaknesses in the studies, comparing studies when appropriate, and pointing out possible future directions. A concluding chapter discusses some of the broader controversies, which have been hinted at throughout the review, in an insightful manner. The use of "league tables" to compare cost-effectiveness ratios is justly criticized, due to the implicit assumption of comparability of studies. The issue of costs versus charges is briefly discussed, and a lengthy discussion of the merits of collecting economic data in clinical trials points to the complementary benefit of modeling. The nature of outcomes used, e.g., the inapplicability of life-years saved as an outcome to evaluate antiemetic therapies, is also explored. By design, this review cannot serve as a complete "how to" guide for economic evaluations, although there are many pearls to be gained from a thorough reading. The economics of cancer prevention and screening, which are in many ways more difficult to study from an economic perspective, were not explored in this text, but there are other sources for this information. Many of the reviewed studies are excellent and may serve as an aide to treatment choices for a specific situation. In a broader sense, this book will be extremely valuable for both the health service researcher who wishes to learn about cancer economics and the cancer researcher interested in the economic aspects of their field. By reviewing 9 years of the literature in a systematic, thoughtful, and critical manner, there is much to be gained for the interested reader who invests a small amount of time reading this excellent work. Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=244

Hold

Place a hold on this item

Copies (1)

Barcode	Call number	Media type	Location	Section	Status
10273-00306	QZ 266/NEY	Book	KCE	Library (10.124)	Available

Cancer Care / Paris : OECD (2013)

Cancer Care : Assuring Quality to Improve Survival [printed text] . - Paris : OECD, 2013 . - 163 p. : ill., ; 22 cm. - (OECD Health Policy Studies) . ISBN : 978-92-64-18096-3 : € 40,00 Languages : English (eng) Descriptors: Classification QZ 266 Neoplasms. Cysts -- Therapy Indexation analysis [Subheading] ; Cancer Care Facilities ; Neoplasms ; Public Policy Abstract: More than five million new cases of cancer are diagnosed every year in OECD countries. Mortality rates are declining, but not as fast as for other big killers such as heart disease, and cancer survival rates show almost a four-fold difference across countries. In short, many countries are not doing as well as they could in the fight against cancer. Cancer Care: Assuring Quality to Improve Survival surveys the policy trends in cancer care over recent years and looks at survival rates to identify why some countries are doing better than others. It sets out what governments should do to reduce the burden of cancer in their countries. As well as an adequate level of resourcing, a comprehensive national cancer control plan appears critical, emphasising initiatives such as early detection and fast-track treatment pathways. Countries also need better data, particularly for patients’ experiences of care, in order to provide high quality, continuously improving cancer care. Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=3327

Hold

Place a hold on this item

Copies (1)

Barcode	Call number	Media type	Location	Section	Status
10273-02837	QZ 266 / CAN	Book	KCE	Library (10.124)	Available

Readers who borrowed this document also borrowed:

PROC SQL by Example	Schreier, Howard
Evidence synthesis for decision making in healthcare	Sutton, Alexander
Bayesian approaches to clinical trials and health-care evaluation	Spiegelhalter, D. J.
Clinical trials	Brody, Tom
A good life in old age?	Organisation for Economic Co-operation and Development, European Commission
Categorical data analysis	Agresti, Alan
Missing data	Allison, Paul David
A visual guide to stata graphics	Mitchel, Michael N.
Sampling	Thompson, Steven K.
Models for discrete data	Zelterman, Daniel
Les techniques de sondage	Ardilly, Pascal

Cancer rehabilitation / Van Weert, Ellen / Rijksuniversiteit Groningen (2007)

Cancer rehabilitation : Effects and Mechanisms [printed text] / Van Weert, Ellen, Author . - Rijksuniversiteit Groningen, 2007 . - 150 p. : ill., ; 24 cm. ISBN : 978-90-367-3132-4 : € 0,00 Proefschrift ter verkrijging van het doctoraat in de Medische Wetenschappen Languages : English (eng) Dutch (dut) Descriptors: Classification QZ 266 Neoplasms. Cysts -- Therapy Indexation Cancer Care Facilities ; Neoplasms ; Quality of Life ; Rehabilitation ; Rehabilitation centers Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=4250

Hold

Place a hold on this item

Copies (1)

Barcode	Call number	Media type	Location	Section	Status
10273-03331	QZ 266 / VAN	Thesis	KCE	Library (10.124)	Available

Ensuring Quality Cancer Care / Hewitt, Maria / Washington, D.C. : National Academy Press (1999)  

Ensuring Quality Cancer Care [printed text] / Hewitt, Maria, Author ; Simone, Joseph, V., Author . - Washington, D.C. : National Academy Press, 1999 . - IX, 246 p. : ill. ; A4. ISBN : 978-0-309-06480-4 : € 34,16 Languages : English (eng) Descriptors: Classification QZ 266 Neoplasms. Cysts -- Therapy Indexation Electronic books ; Neoplasms ; Quality control ; Quality of Health Care ; Therapeutics ; United States Abstract: We all want to believe that when people get cancer, they will receive medical care of the highest quality. Even as new scientific breakthroughs are announced, though, many cancer patients may be getting the wrong care, too little care, or too much care, in the form of unnecessary procedures. How close is American medicine to the ideal of quality cancer care for every person with cancer? Ensuring Quality Cancer Care provides a comprehensive picture of how cancer care is delivered in our nation, from early detection to end-of-life issues. The National Cancer Policy Board defines quality care and recommends how to monitor, measure, and extend quality care to all people with cancer. Approaches to accountability in health care are reviewed. What keeps people from getting care? The book explains how lack of medical coverage, social and economic status, patient beliefs, physician decision-making, and other factors can stand between the patient and the best possible care. The board explores how cancer care is shaped by the current focus on evidence-based medicine, the widespread adoption of managed care, where services are provided, and who provides care. Specific shortfalls in the care of breast and prostate cancer are identified. A status report on health services research is included. Ensuring Quality Cancer Care offers wide-ranging data and information in clear context. As the baby boomers approach the years when most cancer occurs, this timely volume will be of special interest to health policy makers, public and private healthcare purchasers, medical professionals, patient advocates, researchers, and people with cancer. Contents note: 1 INTRODUCTION 13 -- Role of the National Cancer Policy Board, 14 -- Framework of the Report, 15 -- 2 THE CANCER CARE “SYSTEM” 18 -- Elements of the Federal Cancer Care Effort, 18 -- Elements of Cancer Care, 20 -- Individuals Receiving Cancer Care, 20 -- Trajectory of Cancer Care, 22 -- Providers of Cancer Care, 26 -- Sites of Cancer Care, 30 -- The Intersection of Cancer Care and Research, 34 -- Financial Costs of Cancer Care, 35 -- Impact of a Changing Health Care System on Cancer Care, 36 -- Managed Care, 37 -- Self-Funded Health Insurance Plans, 41 -- Key Findings, 41 -- 3 ENSURING ACCESS TO CANCER CARE 46 -- Evidence of Access Problems, 47 -- Why Do These Differences Exist? 47 -- Financial Barriers to Access to Cancer Care, 48 -- Review of the Literature, by Phase of Care, 50 -- Phase 1: Early Detection, 50 -- Phase 2: Evaluation of Abnormal Screening -- Phase 3: Cancer Treatment, 58 -- Phase 4: Posttreatment Surveillance and Recurrence Care, 63 -- Phase 5: End-of-Life Care, 63 -- Key Findings, 66 -- 4 DEFINING AND ASSESSING QUALITY CANCER CARE 79 -- Defining Quality of Care, 79 -- Why Measure Quality of Cancer Care? 80 -- How Is Quality Measured? 80 -- Structural Quality, 80 -- Process Quality, 81 -- Outcomes, 84 -- Variations in Care, 88 -- How Is Quality-of-Care Information Collected? 88 -- Evidence of Cancer Care Quality Problems, 90 -- Breast Cancer, 91 -- Prostate Cancer, 103 -- Key Findings, 108 -- 5 HEALTH CARE DELIVERY AND QUALITY OF CANCER CARE 116 -- Evaluating the Strength of Evidence from Health Services Research, 117 -- Case Volume for Hospitals or Individual Physicians, 118 -- High-Risk Cancer Surgery, 119 -- Prostate Cancer, 125 -- Breast Cancer Surgery, 126 -- Evidence on the Volume–Outcome Relationship from Other Countries, 126 -- Specialization, 128 -- Specialization of Facilities, 128 -- Specialization of Physicians, 130 -- Managed Care Versus Fee-for-Service Care, 133 -- Key Findings, 137 -- 6 CANCER CARE QUALITY ASSURANCE 144 -- Quality Assurance: An Individual Consumer Perspective, 145 -- Choosing Insurers, 145 -- Choosing Physicians and Hospitals, 146 -- Choosing Treatment Options, 148 -- Use of Quality Information by Consumers, 148 -- Quality Assurance: A Market Approach, 150 -- Quality Assurance: The Public-Sector Approach, 151 -- Health Care Financing Administration, 152 -- Public Health Monitoring, 154 -- Agency for Health Care Policy and Research, 154 -- Quality Assurance: The Health Care Professional Approach, 155 -- Joint Commission on Accreditation of Healthcare Organizations, 155 -- National Committee for Quality Assurance, 156 -- American Accreditation Health Care Commission, Inc./URAC, 158 -- Foundation for Accountability, 158 -- American College of Surgeons’ Commission on Cancer, 158 -- Association of Community Cancer Centers, 160 -- Quality Improvement Within Health Care Organizations, 163 -- Practice Guidelines, 164 -- Key Findings, 174 -- 7 HEALTH SERVICES RESEARCH IN CANCER CARE 180 -- What Is Health Services Research? 180 -- Status of Cancer-Related Health Services Research, 181 -- Research Support, 184 -- Federally Sponsored Research, 184 -- Department of Health and Human Services, 184 -- Department of Defense, 199 -- Department of Veterans Affairs, 202 -- Private Organizations Funding Research, 203 -- American Cancer Society, 203 -- The Cochrane Collaboration, 207 -- Key Findings, 207 -- 8 FINDINGS AND RECOMMENDATIONS 211 -- What Is the State of the Cancer Care “System”? 214 -- What Is Quality Cancer Care and How Is It Measured? 215 -- What Problems Are Evident in the Quality of Cancer Care and What Steps -- Can Be Taken to Improve Care? 216 -- How Can We Improve What We Know About the Quality of Cancer Care? 221 -- What Steps Can Be Taken to Overcome Barriers of Access to Quality Cancer Care? 223 -- GLOSSARY 226 -- ACRONYMS 231 -- INDEX 235 Link for e-copy: http://www.nap.edu/openbook.php?record_id=6467&page=R1 Format of e-copy: Webpage Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=2450

Ensuring Quality Cancer Care / Thomas Smith / Richmond [U.S.A.] : Virginia Commonwealth University (1998)  

Ensuring Quality Cancer Care : Clinical Practice Guidelines, Critical Pathways, and Care Maps [printed text] / Thomas Smith, Author ; Bruce E. Hillner, Author . - Richmond [U.S.A.] : Virginia Commonwealth University, 1998 . - 46 p. : ill. ; A4. € 0,00 Languages : English (eng) Descriptors: Classification QZ 266 Neoplasms. Cysts -- Therapy Indexation Evidence-Based Medicine ; Guideline [Publication Type] ; Neoplasms ; Quality of Health Care Contents note: Executive Summary 3 -- Introduction 4 -- The charge 4 -- The need for guidelines 4-6 -- I. The background on guidelines 6 -- Our perspective as clinicians and health service researchers 6 -- The ethics of guidelines 6-7 -- The legal aspects of guidelines 7 -- A practical model to evaluate the likelihood of guideline success 7 -- What guidelines are available and who is making them? 7-8 -- What is the quality of published guidelines? 9-10 -- Guidelines, evidence, and differing philosophies 10-11 -- Barriers to physician compliance 11-12 -- Using guidelines to monitor practice 12 -- The audience for guidelines and their evaluations 12 -- II. Review of the Published Data 12 -- United States -- U.S. 1987: Community Hospital Oncology Program 13-15 -- U.S. 1995: Outcomes management for gynecologic oncology 15-16 -- U.S. 1994: Management of prostatectomy 16 -- U.S. 1997: Model practice management 16-17 -- U.S. 1996: Endoscopic sinus surgery 17 -- U.S. 1995-6: High dose chemotherapy 17 -- U.S. 1994-present: American Society of Clinical Oncology Programs 17-21 -- U.S. 1994: Lung, breast, colorectal cancer management 21-22 -- U.S. 1996: Cancer pain relief in Utah 22-23 -- U.S. 1996: American Urologic Association Programs 23 -- Relevant Experience in the World -- British Columbia, 1991: Early stage breast cancer 24-25 -- Ontario, 1995: Paclitaxel for refractory breast cancer 25 -- Italy, 1987: Italian National Research Council Evaluation of breast, -- colorectal and ovarian cancer guidelines -- 25-28 -- France, 1995: Breast and colorectal cancer 28-29 -- France, 1996: breast and colorectal cancer 29-30 -- Problems anticipated in U.S. medicine based on the available data: evidencebased -- medicine meets demand-based medicine 30-31 -- Summary 32 -- III. Interviews with leaders in the field 33-35 -- IV. Recommendations 36 -- Appendices 37-38 -- References 39-44 Link for e-copy: http://www.iom.edu/~/media/Files/Activity%20Files/Disease/NCPF/BackgroundPaperEn [...] Format of e-copy: PDF [Open Access] Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=2376

New pharmaceuticals for unresectable of met metastatic malignant melanoma / Lorena San Miguel / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2016)  

Permalink

Nieuwe behandelingne van inoperabel of gemetastaseerd kwaadaardig melanoom / Lorena San Miguel / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2016)  

Permalink

Les nouveaux traitements du mélanome malin inéporable ou métastatique / Lorena San Miguel / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2016)  

Permalink

Ondersteunende therapie bij kanker / Kirsten Holdt Henningsen / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2012)  

Permalink

Ondersteunende therapie bij kanker - Deel 2 / Leen Verleye / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2012)  

Permalink

Ondersteunende therapie bij kanker - Deel 3 / Marijke Eyssen / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2013)  

Permalink

Strengthening the Quality of Cancer Services in Ontario / Ontario [Canada] : Cancer Quality Council of Ontario (CQCO) (2003)  

Permalink

Supportive treatment for cancer / Kirsten Holdt Henningsen / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2012)  

Permalink

Supportive treatment for cancer - Part 2 / Leen Verleye / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2012)  

Permalink

Supportive treatment for cancer – Part 3 / Marijke Eyssen / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2013)  

Permalink